| abstract |
The present invention relates to the treatment of patients afflicted with prostate cancer, wherein said treatment comprises administering to a mammal in need thereof at least one tyrosine kinase inhibitor or mast cell inhibitor that is an inhibitor of kinase activity selected from the tyrosine kinases of: c-Kit, PDGFR, LYN, FYN, or any combination thereof, in particular masitinib, optionally in combination with at least one pharmaceutically active ingredient. |